Literature DB >> 1233991

Measurement of plasma prednisolone in man.

C G Wilson, R Ssendagire, C S May, J W Paterson.   

Abstract

1. A modification of the competitive protein binding assay for prednisolone described by English, Chakraborty & Marks (1974) is presented. 2. Addition of pg quantities of [3H]-prednisolone following oral dosage with prednisone or prednisolone. 3. Mean plasma half-life and peak plasma concentrations in patients with respiratory disease seen following prednisolone administration agree well with previous studies in healthy volunteers performed by other workers using competitive protein binding and radioimmunoassay techniques. 4. A considerable inter-patient variation in bioavailability after a standard dose of prednisolone (20 mg) was noted.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233991      PMCID: PMC1402599          DOI: 10.1111/j.1365-2125.1975.tb02778.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

Review 1.  Utility of clinical chemical determinations of drug concentrations in biological fluids.

Authors:  E S Vessell; G T Passananti
Journal:  Clin Chem       Date:  1971-09       Impact factor: 8.327

2.  Measurement of plasma prednisolone by a competitive protein-binding assay.

Authors:  D H Sandberg; C Z Bacallao; W W Cleveland
Journal:  Biochem Med       Date:  1970-12

3.  Radioimmunoassay for prednisolone.

Authors:  W A Colburn; R H Buller
Journal:  Steroids       Date:  1973-06       Impact factor: 2.668

4.  Drug therapy. Serum drug concentrations as therapeutic guides.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1972-08-03       Impact factor: 91.245

5.  The simultaneous estimation of plasma cortisol and transcortin binding characteristics by a competitive protein binding technique.

Authors:  P J Pegg; P M Keane
Journal:  Steroids       Date:  1969-12       Impact factor: 2.668

6.  Sustained-release formulation of prednisolone administered orally to man.

Authors:  P F D'Arcy; J P Griffin; J S Jenkins; W F Kirk; A W Peacock
Journal:  J Pharm Sci       Date:  1971-07       Impact factor: 3.534

7.  Conversion of cortisone to cortisol and prednisone to prednisolone.

Authors:  J S Jenkins; P A Sampson
Journal:  Br Med J       Date:  1967-04-22
  7 in total
  7 in total

1.  Plasma prednisolone levels in man following administration in plain and enteric-coated forms.

Authors:  C G Wilson; C S May; J W Paterson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

2.  Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique.

Authors:  P J Morrison; I D Bradbrook; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

Review 3.  Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.

Authors:  J G Gambertoglio; W J Amend; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

4.  Dose dependent pharmacokinetics of prednisolone.

Authors:  M E Pickup; J R Lowe; P A Leatham; V M Rhind; V Wright; W W Downie
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

5.  Prednisolone absorption in coeliac disease.

Authors:  M E Pickup; F Farah; J R Lowe; J S Dixon; C O Record
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

6.  Disposition of a new steroidal anti-inflammatory agent, deflazacort, in rat, dog and man.

Authors:  A Alessandro; P Antonio; B Giuseppe; P Valeria
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

7.  Plasma prednisolone studies in rheumatic patients.

Authors:  M Hayes; A F Alam; F E Bruckner; S M Doherty; A Myles; J English; V Marks; J Chakraborty
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.